Rubius Therapeutics has two distinct investigational approaches to treat cancer – first, through broad immune system stimulation, and second, through a more direct approach, called antigen-specific stimulation, which is designed to instruct the immune system to target specific types of cancer.
Red Cell Therapeutics for the treatment of cancer are designed to have combinations of cancer-fighting molecules on the cell surface that have the potential to activate and expand the body’s own immune system to attack cancer cells.
Red Cell Therapeutics are engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the surface of the cell have the potential to selectively instruct only those cells of the immune system that have the ability to recognize and attack the tumor.
Rubius Therapeutics’ Red Cell Therapeutics are red blood cells that have been genetically engineered into investigational cellular therapies for the potential treatment of cancer and autoimmune diseases.
Red Cell Therapeutics are administered via infusion into a vein.
Red Cell Therapeutics will be given at the clinical trial center.
We will contact you about your submission